OncoMatch/Blood Cancer — Myeloproliferative (MPN)/CALR

Blood Cancer — Myeloproliferative (MPN)CALR Clinical Trials

CALR exon 9 frameshift mutations (type 1 del52 and type 2 ins5) occur in approximately 25–30% of ET and 25–35% of MF, defining a JAK2-negative MPN subgroup driven by mutant CALR activation of MPL/JAK-STAT signaling. Calreticulin-targeting immunotherapy approaches exploit CALR type 1 mutation neoantigen presentation on MPN cells. Trials investigate CALR-directed T-cell engagers, CALR mutation-specific antibodies, and JAK inhibitor combinations in CALR-mutant MPN.